Literature DB >> 31186275

An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma.

Paul G Murray1,2, Lawrence S Young3.   

Abstract

Although a pathogenic role for the Epstein-Barr virus (EBV) is largely undisputed for tumors that are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt lymphoma), this is not the case for classical Hodgkin lymphoma (cHL), a tumor with only a variable EBV association. In light of recent developments in immunotherapeutics and small molecules targeting EBV, we believe it is now timely to reevaluate the role of EBV in cHL pathogenesis.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2019        PMID: 31186275     DOI: 10.1182/blood.2019000568

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Authors:  Ya Cao; Longlong Xie; Feng Shi; Min Tang; Yueshuo Li; Jianmin Hu; Lin Zhao; Luqing Zhao; Xinfang Yu; Xiangjian Luo; Weihua Liao; Ann M Bode
Journal:  Signal Transduct Target Ther       Date:  2021-01-12

Review 2.  Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Authors:  Selma Addou; Clémentine Sarkozy; Julien Lazarovici; Stéphane Champiat; Aspasia Stamatoullas; Fabrice Jardin; Vincent Ribrag; Aurélien Marabelle; Jean-Marie Michot
Journal:  Hum Vaccin Immunother       Date:  2021-06-08       Impact factor: 4.526

3.  3D image analysis reveals differences of CD30 positive cells and network formation in reactive and malignant human lymphoid tissue (classical Hodgkin Lymphoma).

Authors:  Julia Liebers; Patrick Wurzel; Kerstin Bianca Reisinger; Martin-Leo Hansmann
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

Review 4.  Genomic Landscape of Hodgkin Lymphoma.

Authors:  Magdalena M Brune; Darius Juskevicius; Jasmin Haslbauer; Stefan Dirnhofer; Alexandar Tzankov
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

5.  Macrophage activation syndrome revealing Hodgkin's lymphoma: a case report.

Authors:  Mustapha Mechtoune; Rajae Tissir; Ilias Tazi
Journal:  Pan Afr Med J       Date:  2021-02-03

6.  Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).

Authors:  Jiachen Lu; Jianing Ding; Zhaoxia Liu; Tingtao Chen
Journal:  Int J Oncol       Date:  2022-01-04       Impact factor: 5.650

Review 7.  Proprotein convertases: Key players in inflammation-related malignancies and metastasis.

Authors:  Geraldine Siegfried; Jean Descarpentrie; Serge Evrard; Abdel-Majid Khatib
Journal:  Cancer Lett       Date:  2019-12-30       Impact factor: 8.679

8.  Biophysical Screens Identify Fragments That Bind to the Viral DNA-Binding Proteins EBNA1 and LANA.

Authors:  Troy E Messick; Lois Tolvinski; Edward R Zartler; Anna Moberg; Åsa Frostell; Garry R Smith; Allen B Reitz; Paul M Lieberman
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

9.  Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.

Authors:  Elena Pánisová; Anna Lünemann; Simone Bürgler; Monika Kotur; Julien Lazarovici; Alina Danu; Meike Kaulfuss; Juliane Mietz; Obinna Chijioke; Christian Münz; Pierre Busson; Christoph Berger; David Ghez; Tarik Azzi
Journal:  Cancer Immunol Immunother       Date:  2021-05-15       Impact factor: 6.968

10.  Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.

Authors:  Debmalya Barh; Sandeep Tiwari; Lucas Gabriel Rodrigues Gomes; Marianna E Weener; Khalid J Alzahrani; Khalaf F Alsharif; Alaa A A Aljabali; Murtaza M Tambuwala; Kenneth Lundstrom; Sk Sarif Hassan; Ángel Serrano-Aroca; Kazuo Takayama; Preetam Ghosh; Elrashdy M Redwan; Bruno Silva Andrade; Siomar de Castro Soares; Vasco Azevedo; Vladimir N Uversky
Journal:  Viruses       Date:  2021-09-25       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.